Nanoform Finland Oyj Past Earnings Performance
Past criteria checks 0/6
Nanoform Finland Oyj's earnings have been declining at an average annual rate of -11.1%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 33.1% per year.
Key information
-11.1%
Earnings growth rate
1.6%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 33.1% |
| Return on equity | -35.2% |
| Net Margin | -771.1% |
| Next Earnings Update | 27 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Nanoform Finland Oyj makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3 | -23 | 17 | 0 |
| 30 Jun 24 | 2 | -22 | 17 | 0 |
| 31 Mar 24 | 2 | -23 | 16 | 0 |
| 31 Dec 23 | 3 | -21 | 16 | 0 |
| 30 Sep 23 | 3 | -21 | 15 | 0 |
| 30 Jun 23 | 3 | -22 | 15 | 0 |
| 31 Mar 23 | 3 | -21 | 15 | 0 |
| 31 Dec 22 | 3 | -22 | 15 | 0 |
| 30 Sep 22 | 3 | -22 | 15 | 0 |
| 30 Jun 22 | 3 | -21 | 16 | 0 |
| 31 Mar 22 | 2 | -21 | 15 | 0 |
| 31 Dec 21 | 2 | -20 | 14 | 0 |
| 30 Sep 21 | 1 | -18 | 14 | 0 |
| 30 Jun 21 | 1 | -18 | 12 | 0 |
| 31 Mar 21 | 1 | -19 | 13 | 0 |
| 31 Dec 20 | 1 | -19 | 13 | 0 |
| 30 Sep 20 | 1 | -18 | 11 | 0 |
| 30 Jun 20 | 0 | -16 | 11 | 0 |
| 31 Mar 20 | 0 | -11 | 7 | 0 |
| 31 Dec 19 | 0 | -8 | 5 | 0 |
| 31 Dec 18 | 0 | -2 | 1 | 0 |
| 31 Dec 17 | 0 | -1 | 0 | 0 |
Quality Earnings: 4YL is currently unprofitable.
Growing Profit Margin: 4YL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4YL is unprofitable, and losses have increased over the past 5 years at a rate of 11.1% per year.
Accelerating Growth: Unable to compare 4YL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4YL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).
Return on Equity
High ROE: 4YL has a negative Return on Equity (-35.19%), as it is currently unprofitable.